Esthesioneuroblastoma: The Princess Margaret Hospital experience

Bachar, Gideon; Goldstein, David P.; Shah, Manish D.; Tandon, Asheesh; Ringash, Jolie; Pond, Gregory R.; Gullane, Patrick; Perez-Ordonez, Bayardo; Gilbert, Ralph W.; Brown, Dale; Gentili, Fred; O’Sullivan, Brian; Irish, Jonathan C.

doi:10.1002/hed.20920

Cited by 102 publications

(102 citation statements)

References 28 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most frequent clinical manifestations are nasal obstruction (70%), epistaxis (46%), rhinorrhea, and headache. Anosmia, otalgia, and ocular pain are often present due to the neoplasm's invasion to adjacent structures [2,3,11,12] . During its growth, it extends to the skull base and can spread to the brain or spinal cord.…”

Section: Discussionmentioning

confidence: 99%

Esthesioneuroblastoma: A case with prolonged disease control

et al. 2016

View full text Add to dashboard Cite

Esthesioneuroblastoma, a rare tumor arising from the olfactory vault, varies from being indolent to extremely aggressive. Owing to its rarity, the diagnosis, staging, and treatment of the disease are not well defined. According to a number of small observational retrospective studies and case reports, the disease's actual treatment involves surgery, radiotherapy, and/or chemotherapy (either as a single treatment or used in combination), depending on the disease's staging. Optimal treatment has not been standardized, particularly regarding the role of chemotherapy. We describe a case of advanced esthesioneuroblastoma with prolonged disease control, subjected to a multimodal therapy with surgery, radiotherapy, and chemotherapy, illustrating the benefits of this approach in managing a patient with esthesioneuroblastoma. Herein, we analyze the most important and controversial issues of this type of neoplasia.Keywords: esthesioneuroblastoma; nasal cavity; surgery; radiotherapy; chemotherapy

show abstract

Section: Discussionmentioning

confidence: 99%

Esthesioneuroblastoma: A case with prolonged disease control

et al. 2016

View full text Add to dashboard Cite

show abstract

“…En la siguiente tabla se incluyen los datos de algunas de las series más recientes 2,16,17,37,41,42,48,60 (tabla 6):…”

Section: Revisión Bibliográficaunclassified

“…Sólo en unos pocos estudios se pudo considerar la supervivencia a los 10 años que fue del 52%. Revisando artículos con un número de casos superior a 25 incluyendo estudios más recientes, el rango de supervivencia a los 5 años sería del 55 al 89% y un periodo libre de enfermedad a los 5 años del 36,5 al 76% 2,[16][17]37,41,60 .…”

unclassified

Estudio retrospectivo de 11 casos de estesioneuroblastomas tratados en el Hospital Santa Creu i Sant Pau entre los años 2000 y 2008 más revisión de la literatura

Muñoz¹,

Tresserras²,

Montserrat³

et al. 2011

Neurocirugía

View full text Add to dashboard Cite

“…There is no true standard of care for treatment, because no controlled trials have demonstrated superior outcomes. However, multimodality therapy is generally recommended for all but the smallest of tumors [15,16]. Surgery remains the mainstay of treatment for this malignancy.…”

Section: Surgical Approach To Skull-base Tumorsmentioning

confidence: 99%

Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: A Multidisciplinary Case Presentation from the Joan Karnell Cancer Center of Pennsylvania Hospital

et al. 2010

View full text Add to dashboard Cite

The case of a patient with recurrent esthesioneuroblastoma complicated by ectopic adrenocorticotropic hormone production is presented, including the workup and management of this uncommon complication of an uncommon disease. The Oncologist 2010;15: 51-58 CASE PRESENTATIONIn 1992, a 55-year-old white man presented with epistaxis and was diagnosed with esthesioneuroblastoma. He underwent a craniofacial resection with postoperative radiation therapy to his tumor site. In 1996, he relapsed in the cervical lymph nodes and underwent a bilateral cervical lymph node dissection. In total, eight positive lymph nodes were removed. He was then treated with chemotherapy with etoposide and cisplatin for four cycles. Although radiation therapy to the neck was recommended, the patient refused. In 1998, he relapsed again in the left submandibular area, and two involved lymph nodes were resected. He then agreed to and received radiation therapy to both sides of the neck. In 2002, he had evidence of further disease progression in the posterior nasopharynx and a left preauricular node. In 2004, he was treated with etoposide and carboplatin for four cycles with a minor response. Following that, he was observed without further therapy, given the indolent nature of his disease and minimal symptoms. He did, however, experience focal seizures, occasional epistaxis, hyponatremia, hypothyroidism, and an episode of pneumococcal meningitis.In August 2007, he developed fatigue, confusion, severe hypertension, and proximal muscle weakness. Laboratory studies revealed a serum glucose level of 228 mg/dl (normal, 70 -99 mg/dl), serum potassium of 2.9 mmol/l (normal, 3.5-5.1 mmol/l), pH of 7.570 (normal, 7.350 -7.450

show abstract

Esthesioneuroblastoma: The Princess Margaret Hospital experience

Cited by 102 publications

References 28 publications

Esthesioneuroblastoma: A case with prolonged disease control

Esthesioneuroblastoma: A case with prolonged disease control

Estudio retrospectivo de 11 casos de estesioneuroblastomas tratados en el Hospital Santa Creu i Sant Pau entre los años 2000 y 2008 más revisión de la literatura

Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: A Multidisciplinary Case Presentation from the Joan Karnell Cancer Center of Pennsylvania Hospital

Contact Info

Product

Resources

About